GENOVIS SIGNS GERMAN AND AUSTRIAN DISTRIBUTION AGREEMENT WITH BIOZYM SCIENTIFIC GmbH

Genovis, a producer of new technologies used for Transfection, RNAi, Imaging and Antibody Engineering by life science researchers in industry and academia, announced today that it has signed a distribution agreement with Biozym.

Sarah Fredriksson, Chief Executive Officer of Genovis, said “We are excited about the opportunity this distribution agreement presents for Genovis, it will allow us to reach a large number of customers of Germany and Austria and we are looking forward to working with the experienced team in Biozym”

Biozym was founded 1986 in Hamelin, Germany as a public limited company (GmbH) and provides solutions for the scientific community. The product portfolio consists of high performance instrumentation, superior biochemicals and specialized plastic ware, used in the major molecular biological applications like PCR, DNA-sequencing, identification and purification. The company has showed an extraordinary growth especially during the pioneer years of molecular biology.

Hartmut Groth, Ph.D., General Manager, Biozym Scientific GmbH, said “Biozym Scientific is very pleased to announce that we have entered into a long-term distribution agreement for Germany and Austria with Genovis AB. Our company is well known in the Life Science market in Germany and Austria for more than 20 years as a provider for innovative solutions and the reagents for transfection, imaging and labeling of Genovis AB will make our portfolio even more complete”.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links